Close

Monthly Archives: August, 2020

Ehave Announces Plans to Accelerate the Monetization of its Proprietary Digital Health Platform

Ehave, Inc.,, a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced today it is accelerating plans to monetize its Ehave...

Norton Healthcare is one of first in nation to develop new convalescent plasma study for COVID-19 patients

Norton Healthcare is one of the first in the nation to study convalescent plasma as a therapy to prevent high-risk patients with COVID-19, the...

Amedisys Expands Personal Care Network with BrightStar Care

Amedisys, Inc., America’s leading independent home health, hospice and personal care company, has signed a Care Coordination Agreement with BrightStar Care to add its...

Massachusetts General Hospital researchers create bioluminescent tag to detect DNA break repair

A new bioluminescent reporter that tracks DNA double stranded break (DSB) repair in cells has been developed by researchers from Massachusetts General Hospital (MGH)...

Penn Medicine health system gets $2.5M to study RPM’s effect on COVID-19 disparities

Penn Medicine’s COVID Watch team has received a $2.5 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to study the program’s impact, particularly...

LumiraDx gets FDA EUA status for point-of-care Covid-19 antigen test

LumiraDx has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its point-of-care Covid-19 antigen test. LumiraDx SARS-CoV-2 antigen test...

AXIM Biotechnologies, Empowered Diagnostics collaborate on Covid-19 rapid neutralising antibody test

AXIM Biotechnologies has entered into an exclusive limited licencing, manufacturing and distribution agreement with Empowered Diagnostics on the Covid-19 rapid neutralising antibody test. The deal...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read